KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Cash from Investing Activities: 2020-2025

Historic Cash from Investing Activities for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Sep 2025 value amounting to -$2.5 million.

  • Recursion Pharmaceuticals' Cash from Investing Activities rose 44.13% to -$2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $259.8 million, marking a year-over-year increase of 1552.78%. This contributed to the annual value of $260.1 million for FY2024, which is 2642.62% up from last year.
  • Per Recursion Pharmaceuticals' latest filing, its Cash from Investing Activities stood at -$2.5 million for Q3 2025, which was up 56.11% from -$5.8 million recorded in Q2 2025.
  • Over the past 5 years, Recursion Pharmaceuticals' Cash from Investing Activities peaked at $275.5 million during Q4 2024, and registered a low of -$193.9 million during Q3 2021.
  • For the 3-year period, Recursion Pharmaceuticals' Cash from Investing Activities averaged around $21.3 million, with its median value being -$4.2 million (2024).
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first crashed by 15,828.21% in 2021, then skyrocketed by 11,171.38% in 2024.
  • Quarterly analysis of 5 years shows Recursion Pharmaceuticals' Cash from Investing Activities stood at -$52.2 million in 2021, then soared by 84.73% to -$8.0 million in 2022, then soared by 68.82% to -$2.5 million in 2023, then spiked by 11,171.38% to $275.5 million in 2024, then skyrocketed by 44.13% to -$2.5 million in 2025.
  • Its Cash from Investing Activities stands at -$2.5 million for Q3 2025, versus -$5.8 million for Q2 2025 and -$7.3 million for Q1 2025.